Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
about
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesTirapazamine: a novel agent targeting hypoxic tumor cellsA robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinomaTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerThe relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancerA pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancerReduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma.Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer.Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis.The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.Osteopontin splice variants are differential predictors of breast cancer treatment responsesPleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort studyOsteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma.Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer.Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population.Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer.Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.The tumor microenvironment in non-small-cell lung cancerOsteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.Hypoxia as a Biomarker and for Personalized Radiation Oncology.RNA blood levels of osteopontin splice variants are cancer markers.Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging.
P2860
Q26774750-39C35C7A-64ED-4086-BB12-E5EC89DAB3ABQ27025579-013AA522-6E1E-4A1A-906D-1D351A7F486FQ28302710-32A77ABD-9C2A-4AD1-82EA-A853D9408AEDQ28385552-1166BA65-7806-4D68-A017-00354E8FC3D5Q28396304-B551552D-12FF-44CF-B145-FE2C73BF0746Q30313659-57B13230-9E56-4F08-A77C-7228A2ED284CQ30316284-6CDFFF17-7804-4545-B17E-F1426FC06AB7Q30316974-AA7E9E26-978B-4E4B-9ED0-41D63D3CB570Q30317585-18C221D8-C297-45ED-B617-0D4F940D0F98Q33584942-77FC1462-1325-4140-A497-028CC535082AQ33710746-19AFCF6F-C1AA-4D7D-BD12-D89827D963ABQ34026037-7D6FEA06-4B17-43E0-B0D9-DC0D675143C6Q34371552-020BECCB-BAD9-4801-BE32-38F323FA61BCQ35051314-87B45B85-1744-47C8-BF07-6519A2161241Q35558111-575CCF51-D1BC-4F9B-A5A7-0C1F8916384BQ35593061-4F4F8F73-97AC-4512-B7E5-16576BBF524DQ35753610-9AB3E40A-063E-461B-A8AB-471785FEF2B3Q35863920-A10DE833-7FE5-4E59-AC52-70D7220C9111Q36072882-3A4D2F78-8B96-46F8-8358-AA8FFEB0AB6DQ36076565-129E808A-9FAC-4165-89FB-68BFCC046E71Q36079101-CCFDE3EA-A916-4EA1-AFC9-A024560423AEQ36182815-828A09F1-2968-4997-AC6E-FCC37C71B232Q36238876-F6828A61-C733-456B-A96C-EBC499AE05A9Q36640562-0EAC1EB0-469C-46C0-848E-EDD2F24D1BE0Q36654589-538BCDF1-AB61-426B-BB52-77D9D421A870Q37103777-982D0C01-A4CE-4396-A3A3-F0371F0C1D85Q37213965-F160B17F-2EED-44C8-9BD6-B569633B7871Q37486590-E8E3CDE2-17C8-4A88-A6BC-6F19CE8F78E4Q37777872-17AB8624-36C4-43B0-A26C-9BF0CBE0D65FQ38181994-0F002EED-5A2C-48CE-A8DB-88BDE3D58225Q38824983-ED14FD9C-D568-462C-AB7D-4071F406493CQ38869433-94C17D5F-98CF-4B16-836B-4152C219B551Q39324580-7B6134D7-B8E4-45C4-8165-461E9CBFDBA2Q39424574-EEB81F8B-79BF-4630-B2ED-CE3A92ABFBDFQ40582898-DE28E751-022A-4F1A-A6BB-2591CA3586E3Q42063955-6D44795B-CA80-4551-965F-3A042671CF1FQ46060437-0D6635C2-D095-43C6-8ED9-1650BCE3EF2DQ47131436-61E7D966-A21F-4E61-B9C7-309B46FF5B6EQ47769995-68ABDFBA-150C-4FBA-98E1-21C41BBCBE91Q48506830-56C262F5-323B-4D84-A4D0-706BBE641D9C
P2860
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lower osteopontin plasma level ...... chemotherapy: SWOG Study S0003
@en
Lower osteopontin plasma level ...... hemotherapy: SWOG Study S0003.
@nl
type
label
Lower osteopontin plasma level ...... chemotherapy: SWOG Study S0003
@en
Lower osteopontin plasma level ...... hemotherapy: SWOG Study S0003.
@nl
prefLabel
Lower osteopontin plasma level ...... chemotherapy: SWOG Study S0003
@en
Lower osteopontin plasma level ...... hemotherapy: SWOG Study S0003.
@nl
P2093
P2860
P356
P1476
Lower osteopontin plasma level ...... chemotherapy: SWOG Study S0003
@en
P2093
John J Crowley
Kari Chansky
Mary W Redman
Nichole C Farneth
Philip C Mack
Primo N Lara
Quynh-Thu Le
Stephen K Williamson
Wilbur A Franklin
P2860
P304
P356
10.1200/JCO.2008.17.0662
P407
P577
2008-09-08T00:00:00Z